The role of targeted therapy in the treatment of advanced hepatocellular carcinoma
- Authors: Shakhnovich EB1, Kerbikov OB2, Kulaga EA3
-
Affiliations:
- A.V.Vishnevsky Institute of Surgery of the Ministry of Health of the Russian Federation
- Federal Research Center for Specialized Types of Medical Assistance and Medical Technologies of FMBA of Russia
- M.V.Lomonosov Moscow State University
- Issue: Vol 17, No 1 (2015)
- Pages: 50-54
- Section: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/26999
- ID: 26999
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
E B Shakhnovich
A.V.Vishnevsky Institute of Surgery of the Ministry of Health of the Russian Federation
Email: shakhnovich@yandex.ru
врач-онколог, ФГБУ Институт хирургии им. А.В.Вишневского 117997, Russian Federation, Moscow, ul. Bol'shaia Serpukhovskaia, d. 27
O B Kerbikov
Federal Research Center for Specialized Types of Medical Assistance and Medical Technologies of FMBA of Russiaканд. мед. наук, ст. науч. сотр. ФГБУ ФНКЦ специализированных видов медицинской помощи и медицинских технологий 115682, Russian Federation, Moscow, Orekhovyi bul'var, d. 28
E A Kulaga
M.V.Lomonosov Moscow State Universityаспир. фак-та фундаментальной медицины ФГБОУ ВПО МГУ им. М.В.Ломоносова 119192, Russian Federation, Moscow, Lomonosovskii pr., d. 31, korp. 5
References
- Sangiovanni A, Prati G.M, Fasani P et al. The natural history of compensated cirrhosis due to hepatitis C virus a 17-year cohort study of 214 patients. Hepatology 2006; 43: 1303-10.
- EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-43.
- Bruix J, Sherman M. Management of Hepatocellular Carcinoma: An Update. Hepatology 2011; 53 (3).
- Verslype C, Rosmorduc O, Rougier P. ESMO Guidelines Working Group. Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow - up. Ann Oncol 2012; 23 (Suppl. 7): vii41-8.
- http://nccn.org
- Практические рекомендации по лекарственному лечению больных первичным раком печени Российского общества клинической онкологии (RUSSCO). Версия 2014; с. 243-52.
- Wilhelm S, Carter C, Lynch M et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Dis 2006; 5 (10): 835-44.
- Abou-Alfa G.K, Schwartz L, Ricci S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24 (26): 4293-300.
- Abou-Alfa G.K, Johanson P, Knox J et al. Preliminary results from Phase II, randomized, double - blind study of sorafenib plus doxorubicin vs. placebo plus doxorubicin in patients with advanced hepatocellular carcinoma. ECCO 14 - European Cancer Conference. Barselona, Spain, 23-27 Sept. 2007.
- Cheng A.L, Kang Y.K, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double - blind, placebo - controlled trial. Lancet Oncol 2009; 10 (1): 25-34.
- Llovet J.M et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359 (4): 378-90.
- Marrero J et al. Final analysis of GIDEON (Global Investigation of the rapeutic DEcisions in hepatocellular carcinoma and of its treatment with sorafeNib) in >3000 sorafenib - treated patients: clinical findings in patients with liver dysfunction. Poster presented at the Annual Meeting of the American Society of Clinical Oncology. May 31 - June 4 2013. Chicago, Illinois USA.
- Faivre S, Raymond E, Boucher E et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open - label, multicentre, phase II study. Lancet Oncol 2009; 10 (8): 794-800.
- Johnson P.J, Qin S, Park J.W et al. Brivanib vs. sorafenib as first - line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol 2013; 31 (28): 3517-24.
- Boige V, Malka D, Bourredjem A et al. Efficacy, safety, and biomarkers of single - agent bevacizumab therapy in patients with advanced hepatocellular carcinoma. Oncologist 2012; 17 (8): 1063-72.
- Zhu A.X, Kudo M, Assenat E et al. EVOLVE-1: Phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib. Abstr. J Clin Oncol 2014; 32 (Suppl. 3): 172.